{"id":536258,"date":"2021-09-09T08:04:43","date_gmt":"2021-09-09T12:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/"},"modified":"2021-09-09T08:04:43","modified_gmt":"2021-09-09T12:04:43","slug":"monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/","title":{"rendered":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMETTE, Ill., Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,\u00a0is\u00a0scheduled\u00a0to present a Company overview at the\u00a0following investor conferences\u00a0in September:<\/p>\n<p>\n        <strong>H.C.\u00a0Wainwright 23<\/strong><br \/>\n        <sup><br \/>\n          <strong>rd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Global Investment Conference<\/strong>\u00a0<br \/>The Company\u2019s presentation will be webcast on Monday, September 13, 2021\u00a0at 7:00 a.m. ET\u00a0<\/p>\n<p>\n        <strong>Cantor Virtual Global Healthcare\u00a0Conference 2021<\/strong>\u00a0<br \/>The Company\u2019s presentation will be webcast on Thursday, September 30, 2021\u00a0at\u00a011:20 a.m. ET, Track 7<\/p>\n<p>\n        <strong>About\u00a0Monopar\u00a0Therapeutics\u00a0Inc.\u00a0<\/strong><\/p>\n<p>Monopar\u202fTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.\u202fMonopar&#8217;s\u202fpipeline consists of\u202fValidive\u202ffor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin\u202ffor the treatment\u202fof advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FXr1dNzcKqxIOtbs7zNfjlHZLH9Z55TUtP8SKCXgsssdy0Aei6GEW89ssbQVy1v_2j7z9kpUH7A_8-SOZAUU8A==\" rel=\"nofollow noopener\" target=\"_blank\">www.monopartx.com<\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\u00a0\u00a0<\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong><br \/>\n        <br \/>Investor Relations\u00a0\u00a0<br \/>Kim R. Tsuchimoto\u00a0\u00a0<br \/>Chief Financial Officer\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3YAvJzCH-GLXPGSKXz1DEd0JzUua3N_hDupoHA3Xw_mZSgKRHPAdb3zYSQwkcK9ZE8O4XZ6ehNSpjISR-_5M3D_2HnjC9hPe2LdSR0yQkvE=\" rel=\"nofollow noopener\" target=\"_blank\">kimtsu@monopartx.com<\/a>\u00a0\u00a0<\/p>\n<p>Follow Monopar on social media for updates:\u00a0<\/p>\n<p>Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D8vkXqrzIHp73UbxU9m0YZ44yNou2I_cJNEnnOKmDMK3nkzFe-agnmOJ58oKGzJYg6BhlR9-ckdq-viD6MzyzA==\" rel=\"nofollow noopener\" target=\"_blank\">@MonoparTx<\/a>\u00a0 LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OpH2v-fyCfXK_4SG7Gou9yTUEBz-AwAvQ-iaHl5YCfNmZsWyOqtXWss4ez7I3QY-l-X61iftiQPtlclvA6OtqeZy2m9kbJ21a-VLCwPjDO3vrJrWP8ajM-HkX4xL3ekqYrd1zXPulSykVHBszl7kMA==\" rel=\"nofollow noopener\" target=\"_blank\">Monopar Therapeutics<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2VkMTg2MzQtNzA0YS00NWNlLThmMzctMzFiNzYxODI3MGE5LTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,\u00a0is\u00a0scheduled\u00a0to present a Company overview at the\u00a0following investor conferences\u00a0in September: H.C.\u00a0Wainwright 23 rd Annual Global Investment Conference\u00a0The Company\u2019s presentation will be webcast on Monday, September 13, 2021\u00a0at 7:00 a.m. ET\u00a0 Cantor Virtual Global Healthcare\u00a0Conference 2021\u00a0The Company\u2019s presentation will be webcast on Thursday, September 30, 2021\u00a0at\u00a011:20 a.m. ET, Track 7 About\u00a0Monopar\u00a0Therapeutics\u00a0Inc.\u00a0 Monopar\u202fTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.\u202fMonopar&#8217;s\u202fpipeline &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar Therapeutics to Present at Upcoming Investor Conferences in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536258","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,\u00a0is\u00a0scheduled\u00a0to present a Company overview at the\u00a0following investor conferences\u00a0in September: H.C.\u00a0Wainwright 23 rd Annual Global Investment Conference\u00a0The Company\u2019s presentation will be webcast on Monday, September 13, 2021\u00a0at 7:00 a.m. ET\u00a0 Cantor Virtual Global Healthcare\u00a0Conference 2021\u00a0The Company\u2019s presentation will be webcast on Thursday, September 30, 2021\u00a0at\u00a011:20 a.m. ET, Track 7 About\u00a0Monopar\u00a0Therapeutics\u00a0Inc.\u00a0 Monopar\u202fTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.\u202fMonopar&#8217;s\u202fpipeline &hellip; Continue reading &quot;Monopar Therapeutics to Present at Upcoming Investor Conferences in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar Therapeutics to Present at Upcoming Investor Conferences in September\",\"datePublished\":\"2021-09-09T12:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/\"},\"wordCount\":220,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/\",\"name\":\"Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\",\"datePublished\":\"2021-09-09T12:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar Therapeutics to Present at Upcoming Investor Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk","og_description":"WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,\u00a0is\u00a0scheduled\u00a0to present a Company overview at the\u00a0following investor conferences\u00a0in September: H.C.\u00a0Wainwright 23 rd Annual Global Investment Conference\u00a0The Company\u2019s presentation will be webcast on Monday, September 13, 2021\u00a0at 7:00 a.m. ET\u00a0 Cantor Virtual Global Healthcare\u00a0Conference 2021\u00a0The Company\u2019s presentation will be webcast on Thursday, September 30, 2021\u00a0at\u00a011:20 a.m. ET, Track 7 About\u00a0Monopar\u00a0Therapeutics\u00a0Inc.\u00a0 Monopar\u202fTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.\u202fMonopar&#8217;s\u202fpipeline &hellip; Continue reading \"Monopar Therapeutics to Present at Upcoming Investor Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:04:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September","datePublished":"2021-09-09T12:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/"},"wordCount":220,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/","name":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=","datePublished":"2021-09-09T12:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjY2NyM0Mzk2MTc0IzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-therapeutics-to-present-at-upcoming-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar Therapeutics to Present at Upcoming Investor Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536258"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}